Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e075286-e075286
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 44
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
Eurosurveillance (2023) Vol. 28, Iss. 7
Open Access | Times Cited: 33
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1711-1711
Open Access | Times Cited: 22
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies
Qingwen He, Yaling An, Xuemei Zhou, et al.
Med (2024) Vol. 5, Iss. 5, pp. 401-413.e4
Closed Access | Times Cited: 11
Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study
Susana Monge, James Humphreys, Nathalie Nicolay, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 4
Open Access | Times Cited: 11
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 9
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Vaccine (2024) Vol. 42, Iss. 15, pp. 3389-3396
Open Access | Times Cited: 8
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023
Eero Poukka, Jori Perälä, Hanna Nohynek, et al.
Eurosurveillance (2024) Vol. 29, Iss. 37
Open Access | Times Cited: 7
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis
Meng-qun Cheng, Rong Li, Zhiying Weng, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 5
Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
Marek Petráš, D Janovská, Danuše Lomozová, et al.
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106986-106986
Open Access | Times Cited: 5
Methodological challenges using routine clinical care data for real-world evidence: a rapid review utilizing a systematic literature search and focus group discussion
Michelle Pfaffenlehner, Max Behrens, Daniela Zöller, et al.
BMC Medical Research Methodology (2025) Vol. 25, Iss. 1
Open Access
Morris responds to “Critical analyses concerning COVID-19 vaccines need to be consistently critical, and informed”
Jeffrey S. Morris
American Journal of Epidemiology (2025)
Closed Access
Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey
Thomas Ward, Robert S. Paton, Christopher E. Overton, et al.
Journal of Infection (2025), pp. 106461-106461
Open Access
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy
Abby E. Rudolph, Farid Khan, Amy Shah, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 3, pp. 648-659
Open Access | Times Cited: 14
Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study
Ramandip Grewal, Sarah A. Buchan, Lena Nguyen, et al.
The Journal of Infectious Diseases (2023)
Open Access | Times Cited: 12
Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023
Jennifer DeCuir, Diya Surie, Yuwei Zhu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era
Kye Hun Kim
Journal of Lipid and Atherosclerosis (2024) Vol. 13, Iss. 1, pp. 21-21
Open Access | Times Cited: 4
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Felippe Lazar Neto, Matt D. T. Hitchings, Avnika B. Amin, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100755-100755
Open Access | Times Cited: 4
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector P. Rodríguez, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1194-1203
Open Access | Times Cited: 10
COVID-19 Vaccine Effectiveness Among Adolescents
Eero Poukka, Niklas Worm Andersson, Emilia Myrup Thiesson, et al.
PEDIATRICS (2024) Vol. 153, Iss. 2
Closed Access | Times Cited: 3
Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates
Deborah Cromer, Arnold Reynaldi, Ainslie Mitchell, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023
Ian D. Plumb, Melissa Briggs Hagen, Ryan E. Wiegand, et al.
Vaccine (2023) Vol. 42, Iss. 10, pp. 2543-2552
Open Access | Times Cited: 9
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
Mario Fontán‐Vela, Esther Kissling, Nathalie Nicolay, et al.
Eurosurveillance (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
Jennifer DeCuir, Diya Surie, Yuwei Zhu, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 11
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top